Alprazolam is a benzodiazepine indicated for the acute treatment of generalized anxiety disorder (GAD) in adults, among other approved uses. It is available as tablets, extended-release tablets and orally disintegrating tablets. MedsAcross supplies Alprazolam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Alprazolam is indicated for the: • acute treatment of generalized anxiety disorder (GAD) in adults. • treatment of panic disorder (PD), with or without agoraphobia in adults. Alprazolam is a benzodiazepine indicated for the: • Acute treatment of generalized anxiety disorder in adults. • Treatment of panic disorder with or without agoraphobia in adults.
Source: US FDA prescribing information
Alprazolam is a 1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma‑aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Source: US FDA prescribing information
• Generalized Anxiety Disorder: o Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily. o Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses. o Use the lowest possible effective dose and frequently assess the need for continued treatment. • Panic Disorder: Recommended starting oral dosage is 0.5 mg three times daily. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. • When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. • See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir.
Source: US FDA prescribing information
Alprazolam is contraindicated in patients: • with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported. • taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir • Known hypersensitivity to alprazolam or other benzodiazepines. • Concomitant use with strong cytochrome P450 3A (CYP3A) inhibitors, except ritonavir.
Source: US FDA prescribing information
Boxed warning: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. • Effects on Driving and Operating Machinery: Patients receiving alprazolam should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. • Patients with Depression: Exercise caution in patients with signs or symptoms of depression. Prescribe the least number of tablets feasible to avoid intentional overdosage.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: • Risks from Concomitant Use with Opioids • Abuse, Misuse, and Addiction • Dependence and Withdrawal Reactions • Effects on Driving and Operating Machinery • Patients with Depression • Neonatal Sedation and Withdrawal Syndrome • Risks in Patients with Impaired Respiratory Function The most common adverse reactions reported in clinical trials for generalized anxiety disorder and panic disorder (incidence > 5% and at least twice that of placebo) include: impaired coordination, hypotension, dysarthria, and increased libido.
Source: US FDA prescribing information
• Use with Opioids: Increase the risk of respiratory depression. • Use with Other CNS Depressants: Produces additive CNS depressant effects. • Use with Digoxin: Increase the risk of digoxin toxicity. • Use with CYP3A Inhibitors (except ritonavir): Increase the risk of adverse reactions of alprazolam. • Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam.
Source: US FDA prescribing information
Store at controlled room temperature 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
19 presentations of Alprazolam, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Alprazolam 0.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 1 mg tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 0.25 mg tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 2 mg tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 0.5 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 1 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 2 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 3 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 0.5 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Xanax 1 mg tabletOral | Pharmacia & Upjohn | US FDA | Available on request |
| Alprazolam 0.25 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 1 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Alprazolam 2 mg orally disintegrating tabletOralGeneric name | — | US FDA | Available on request |
| Xanax 0.25 mg tabletOral | Viatris Specialty | US FDA | Available on request |
| Xanax 0.5 mg tabletOral | Viatris Specialty | US FDA | Available on request |
| Alprazolam 1 mg/mL oral concentrateOralGeneric name | — | US FDA | Available on request |
| Xanax 2 mg tabletOral | Viatris Specialty | US FDA | Available on request |
| Xanax XR 2 mg extended-release tabletOral | Viatris Specialty | US FDA | Available on request |
| Xanax XR 3 mg extended-release tabletOral | Viatris Specialty | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 16 October 1981 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Alprazolam in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 19 presentations of Alprazolam and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Alprazolam, including Xanax, Xanax XR.
Yes. The US FDA first approved Alprazolam on 16 October 1981, according to Drugs@FDA.
No listed presentation of Alprazolam is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Alprazolam is classified under ATC code N05BA12 (Alprazolam).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.